1. Letter by Mitchell et al Regarding Article, 'Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment'
- Author
-
Hilary Longhurst, William E. White, Daniel M. Reed, Ginger L. Milne, Rebecca Knowles, Magdi Yaqoob, Melissa V. Chan, Jane A. Mitchell, Nicholas S. Kirkby, Timothy D. Warner, Darryl C. Zeldin, and Matthew L Edin
- Subjects
0301 basic medicine ,Physiology ,Phospholipases A2, Cytosolic ,Prostaglandin ,6-Ketoprostaglandin F1 alpha ,030204 cardiovascular system & hematology ,Kidney ,1102 Cardiovascular Medicine And Haematology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Loss of Function Mutation ,Humans ,Cells, Cultured ,1103 Clinical Sciences ,Middle Aged ,Allografts ,Kidney Transplantation ,Epistemology ,Thromboxane B2 ,Phenotype ,030104 developmental biology ,Cardiovascular System & Hematology ,chemistry ,Prostaglandin-Endoperoxide Synthases ,Female ,Cardiology and Cardiovascular Medicine ,Biomarkers - Abstract
We would like to thank Dr Grosser et al1 for their continued interest in our work. While we may not agree with their arguments or their opinions of our study,2 we welcome debate in this extremely important area. We take this opportunity to address the points that they raise. First, although urine may well be a convenient compartment within which to measure markers of prostacyclin and thromboxane A2, numerous observations,3–10 of which ours is only the latest,2 indicate that they poorly reflect production within the circulation and the reactivities of endothelial cells and platelets. Second, the literature that Grosser et al1 cite is somewhat selective and in places inaccurate. For example, reference 3,11 which the authors cite to substantiate the statement “Most insights into the in vivo biology and pharmacology of the prostaglandin pathway have derived from the …
- Published
- 2018